Cabaletta Bio to Present at Upcoming Investor Conferences in October

Noble Horvath

Press release content from Globe Newswire. The AP news staff was not involved in its creation. https://apnews.com/press-release/globe-newswire/corporate-news-products-and-services-business-health-care-industry-health-f66962ca4cf26a242a7a6943d39f9093 Click to copy PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with […]

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the following three upcoming investor conferences in October:

  • Stifel 2020 Immunology and Inflammation Virtual Summit: “The Potential for Treg Modifying and CAR T Therapies in Immunology” panel on Thursday, October 1, 2020 at 3:00 p.m. ET.
  • Jefferies Virtual Cell Therapy Summit: Fireside chat on Monday, October 5, 2020 at 8:30 a.m. ET.
  • Chardan 4th Annual Genetic Medicines Conference: Fireside chat on Tuesday, October 6, 2020 at 11:30 a.m. ET.

A live webcast of these presentations will be available on the News and Events section of the company’s website at www.cabalettabio.com. Following the presentations, a replay of the webcast will be available on the website for 90 days.

About Cabaletta Bio
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA) platform, in combination with Cabaletta’s proprietary technology, utilizes Chimeric AutoAntibody Receptor (CAAR) T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ Phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please see www.clinicaltrials.gov. The Company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit www.cabalettabio.com.

Contacts:
Anup Marda
Chief Financial Officer
[email protected]

Sarah McCabe
Stern Investor Relations, Inc.
[email protected]

Next Post

8 essential travel items for travelling in winters

This is the time of year when the weather is changing. There’s a nip in the air and the sweaters are out. And we can’t emphasise enough that this is the best time to go to the mountains. Hot soupy noodles and oversized hoodies make for a perfect combination by […]